Company intelligence / Profile preview

ANACONDA Consultants

Ownership: Private
Development stage: Other

Overview

Anaconda Biomed has developed the ANA (Advanced Neurovascular Access) funnel catheter system for mechanical thrombectomy in acute ischemic stroke. Preclinical and early clinical studies have demonstrated safety and efficacy. The device aims to improve clot retrieval efficiency and reduce complications during thrombectomy procedures.

In vitro, in vivo (swine model), and initial human studies have been published showing promising results for clot removal with reduced risk of fragmentation or embolization.

The ATHENA clinical trial has begun enrolling patients in the U.S.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on ANACONDA Consultants.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANACONDA Consultants.

Explore the full profile